

# **Open End PERLES on UBS Bloomberg CMCI Nickel Excess Return Index - 3 Months**



# **Final Terms**

| Product Details   Underlying / Underlying ndex UBS Bloomberg Constant Maturity   Nickel USD Excess Return Index – 3 Months (the "Index")   (Bloomberg: CTLNER3M) |  |                                  |                   | ths (the "Index")                |
|--|--|----------------------------------|-------------------|----------------------------------|
|  | es the uncollateralized  |                                  |                   |                                  |
| Issue Amount   | 10'000   | Open End PERLES (wit             | h reopening cl    | ause)                            |
| Conversion<br>Reference Level of<br>Underlying Index   | 1 Open End PERLES refers to the level of one Underlying Index<br>1327.14   |                                  |                   |                                  |
| Issue Price  | USD 132  | 27.14 (100% of Refer             | ence Level of L   | Inderlying Index)                |
| Security No./ Codes  | ISIN:<br><b>Valor:</b>   | CH0031793927<br><b>3 179 392</b> | WKN: UB<br>Common | 1N1U                             |
| Dates  |  |                                  |                   |                                  |
| Issue Date   | 6 June 2   | 2007                             |                   |                                  |
| Pricing Date   | 6 June 2007<br>13 June 2007<br>Open End<br>means the day when the Investor's Exercise Right and/or the Issuer's Call Right<br>becomes effective.<br>means the <b>5<sup>th</sup> Business Day</b> following the Effective Exercise Date. In case this date<br>is not a Business Day the next following Business day will apply.                   |                                  |                   |                                  |
| Payment Date   |  |                                  |                   |                                  |
| Expiration Date  |  |                                  |                   |                                  |
| Effective Exercise Day   |  |                                  |                   |                                  |
| Redemption Date  |  |                                  |                   |                                  |
| Product Description  |  |                                  |                   |                                  |
|  | With an Open End PERLES the investor can participate in the performance of the<br>Underlying. The downside risk is similar to that of the Underlying, i.e. the investor<br>could lose his total investment if the Underlying value falls to zero. Open End<br>PERLES are a product for investors who expect the Underlying to increase in value. |                                  |                   |                                  |
| General Information  |  |                                  |                   |                                  |
| lssuer   | UBS AG, London Branch (Rating Aaa / AA+)   |                                  |                   |                                  |
| Lead Manager   | UBS AG, Zurich (UBS Investment Bank)<br>UBS AG, London Branch<br>Cash Settlement in USD<br>ay A day at which the Underlying Index is calculated and published by the Index<br>Sponsors.  |                                  |                   |                                  |
| Calculation Agent  |  |                                  |                   |                                  |
| Settlement   |  |                                  |                   |                                  |
| Exchange Business Day  |  |                                  |                   | lated and published by the Index |
| UBS Investment Bank is a business grou   | ip of UBS AG   |                                  | Contact:          | UBS AG, P.O. Box, 8098 Zurich    |

| UBS Investment Bank is a business group of UBS AG   | Contact:   | UBS AG, P.O. Box, 8098 Zurich   |
|---|--|---|
| This document is for your information only and is not intended to be an offer, or a solicitation of<br>an offer, to buy or sell any financial product. The information and opinions contained in this<br>document have been compiled from or arrived at in good faith from sources believed to be<br>reliable. No representation or warranty, express or implied as to the accuracy or completeness or<br>the information contained herein is made by UBS AGC. All opinions expressed herein are subject<br>to change without notice. Futures and Options trading is considered risky, and past performance<br>is not necessarily indicative for future results. Additional note to persons receiving this document<br>in Italy: Any Italian persons receiving this document and requiring further information should<br>contact Giubergia UBS SIM SpA, an affiliate of UBS SA, in Milan. | Institutional Investors:<br>Private Investors:<br>E-Mail:<br>Internet: | Zurich: +41-44-239 68 00*<br>Geneva: +41-22-389 50 05*<br>0848-911-011*<br>derivatives@ubs.com<br>www.ubs.com/keyinvest |

This document is not intended for distribution into the USA, to U.S. Persons.

Please note that calls made to the numbers marked with an asterisk  $({}^{\star})$  may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.



| Exchange(s)                          | The exchanges on which components comprising the Underlying Index are traded, as determined by the Index Sponsors from time to time.  |
|--------------------------------------|---|
| Index Sponsors                       | UBS AG, Bloomberg L.P.  |
| Trading                              | Indicative Prices will be available on Reuters UBSDEEW05 and www.ubs.com/keyinvest from 11:00 to 17:30 CET  |
| Clearing                             | SIS, Euroclear, Clearstream (booked at SIS SegaInterSettle AG)  |
| Listing                              | No listing  |
| lssuer Call Right                    | The Issuer has the annual right, on 13 June, for the first time on 13 June 2008 ("Notice Date"), to call the Open End PERLES for early redemption, at the value of the current Underlying Index level, effective 1 year after "Notice Date" has been published to that effect (in case that any of the dates is not a business day, the next following business day applies)  |
| Investor Exercise Right              | In addition to the possibility to sell the Open End PERLES at any time, each investor<br>has an annual right to exercise their Open End PERLES for the value of the current<br>Underlying Index level. The notice has to be received not later than 10 am CET on<br>13 June. The exercise will become effective as of close of business on 13 June of<br>the relevant year (in case that this day is not a business day, the next following<br>business day applies). |
| Form of deed                         | Book – entry Security   |
| Selling restrictions                 | Europe, Hong Kong, Singapore, UK, USA, U.S. persons   |
|                                      | Warning – The contents of this document have not been reviewed by any regulatory authority in Hong Kong. Investors are advised to exercise caution in relation to the offer. If an investor is in any doubt about any of the contents of this document, the investor should obtain independent professional advice.   |
| Governing Law                        | Swiss / Zurich  |
| Jurisdiction<br>SVSP-Kategorisierung | Tracker-Zertifikate (210)   |
| Tax Information                      |   |
| Swiss Tax Treatment                  | Swiss Stamp Duty<br>Secondary market transactions are not subject to Swiss Stamp Duty.<br>Swiss Income Tax<br>The transaction is subject to neither Swiss federal nor cantonal and communal<br>Income Tax.<br>Swiss Withholding Tax   |
| EU Savings Tax                       | The product is not subject to the Swiss Withholding Tax.<br>For Swiss paying agents, the product is not subject to the EU Savings Tax (TK14).   |

# Description of the UBS Bloomberg Constant Maturity Index Family (CMCI)

The UBS Bloomberg CMCI family is designed as an international benchmark for modern commodity investment. It is composed of a basket of 28 commodity futures with a series of up to 7 different investment maturities for each individual commodity using the calculation methodology of constant maturity forwards. For more information on the UBS Bloomberg CMCI family see <u>www.ubs.com/cmci</u>

## Information with regard to the Underlying

Information with regard to the Underlying consists of extracts from or summaries of information that is publicly available in respect of the Underlying and is not necessarily the latest information available. The Issuer accepts responsibility for accurately extracting and summarizing the underlying information. No further or other responsibility (express or implied) in respect of the underlying information is accepted by the Issuer. The Issuer makes no representation that the underlying information, any other publicly available information or any other publicly available documents regarding the underlying asset, index or other item(s) to which the certificates relate are accurate or complete.

#### **Index Disclaimer**

| UBS Investment Bank is a business group of UBS AG  | Contact:   | UBS AG, P.O. Box, 8098 Zurich   |
|--|--|---|
| This document is for your information only and is not intended to be an offer, or a solicitation<br>of an offer, to buy or sell any financial product. The information and opinions contained in this<br>document have been compiled from or arrived at in good faith from sources believed to be<br>reliable. No representation or warranty, express or implied as to the accuracy or completeness<br>or the information contained herein is made by UBS AG. All opinions expressed herein are<br>subject to change without notice. Futures and Options trading is considered risky, and past<br>performance is not necessarily indicative for future results. Additional note to persons receiving<br>this document in Italy: Any Italian persons receiving this document and requiring further<br>information should contact Giubergia UBS SIM SpA, an affiliate of UBS SA, in Milan. | Institutional Investors:<br>Private Investors:<br>E-Mail:<br>Internet: | Zurich: +41-44-239 68 00*<br>Geneva: +41-22-389 50 05*<br>0848-911-011*<br>derivatives@ubs.com<br>www.ubs.com/keyinvest |
| This document is not intended for distribution into the USA, to U.S. Persons.  |  | he numbers marked with an asterisk (*) may be<br>f these numbers, we shall assume that you consent to                   |



This material is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any recipient. It is for information purposes only and should not be construed as an offer, recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The Index Sponsors make no representation or warranty, express or implied, regarding the appropriateness of investing in products referenced to the UBS Bloomberg Constant Maturity Commodity Index ("CMCI"), commodity products in general or of the ability of the CMCI to track commodity market performance. In determining the constituents of the CMCI and any amendment thereto, the Index Sponsors have no obligation to consider the needs of any counterparties that have products referenced to the CMCI. The Index Sponsors have all proprietary rights with respect to the CMCI. Any third party product based on or in relation to the CMCI ("Product") may only be issued upon the prior written approval of UBS and upon the execution of a license agreement between UBS and the party intending to launch a Product. In no way does UBS, endorse or have any other involvement in the issue and offering of a Product. UBS makes no representation or warranty, express or implied, to the holders of the Products or any member of the public regarding the advisability of investing in the Product or commodities generally or in futures particularly, or as to results to be obtained from the use of the Index or from the Product. Past performance of the CMCI is not necessarily indicative of future results.

© UBS 2007 The key symbol and UBS are among the registered and unregistered trademarks of UBS. Bloomberg is a trademark of Bloomberg L.P. UBS Bloomberg Constant Maturity Commodity Index, UBS Bloomberg CMCI and CMCI are service marks of UBS and/or Bloomberg. All rights reserved.

THE INDEX SPONSORS DO NOT GUARANTEE THE QUALITY, ACCURACY AND/OR THE COMPLETENESS OF THE CMCI OR ANY DATA INCLUDED THEREIN AND SHALL NOT HAVE ANY LIABILITY FOR ANY ERRORS OR OMISSION OR INTERRUPTIONS IN THE CALCULATION AND/OR DISSEMINATION OF THE CMCI. THE INDEX SPONSORS MAKE NO WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY OR FROM THE USE OF THE CMCI OR ANY DATA INCLUDED THEREIN OR FOR ANY OTHER USE (WHETHER DIRECTLY OR VIA ANY PRODUCT REFERENCED THERETO). UBS MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND TO THE EXTENT PERMITTED BY LAW HEREBY EXPRESSLY DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE CMCI OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, TO THE EXTENT PERMITTED BY LAW UBS DISCLAIMS ANY LIABILITY FOR ANY PUNITIVE, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS), EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH.

You should be aware that the New York Mercantile Exchange, Inc. (including the COMEX division), Chicago Board of Trade, ICE Futures, European Energy Exchange, London Metal Exchange, Kansas City Board of Trade, New York Board of Trade, Winnipeg Commodities Exchange, Europext.Liffe, the Chicago Mercantile Exchange and a number of future exchanges (collectively the "Exchanges") provide data on commodity futures contracts which, in part, are used to compile and calculate the CMCI. However, the Exchanges provide such data "as is" and without representation or warranty on their part.

Further, the Exchanges: (i) do not in any way participate in the offering, sale, administration of, or payments for, the CMCI or any products related thereto, (ii) do not in any way ensure the accuracy of any of the statements made in any product materials or this document, (iii) are not liable for any error or omission in any settlement or other price, index, or valuation used in connection with the CMCI, have not participated in the determination of the timing of, prices at, or quantities of the products to be issued and have no obligation or liability in connection with the administration, marketing, or trading of the CMCI or any products thereon, (iv) are not in any way an issuer, manager, operator, guarantor or offeror of CMCI or any products related thereto, and are not a partner, affiliate or joint venturer of any of the foregoing, (v) have not approved, sponsored or endorsed the CMCI or its terms and are not responsible for any calculations involving the Index, (vi) make no representation or warranty, express or implied, to the owners of the CMCI or any member of the public regarding the advisability of investing in securities generally or in the CMCI particularly, and (vii) have no involvement with and accept no responsibility for the CMCI, its suitability as an investment or its future performance.

None of the information contained herein constitutes a solicitation, offer, opinion, or recommendation by the Index Sponsors to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services regarding the profitability or suitability of any security or investment. The Index Sponsors disclaim any liability to any party for any inaccuracy in Index or any Product based on the Index, for any mistakes, errors, omissions or interruptions in the calculation and/or dissemination of the Index, or for the manner in which it is applied in connection with the issue and offering of a Product. Under no circumstances, including but not limited to negligence, shall the Index Sponsors, their parents, and their respective affiliates, suppliers, agents, directors, officers, employees, representatives, general partner, subsidiaries, successors, and assigns be liable for direct, indirect, incidental, consequential, special, punitive, or exemplary damages even if the Index Sponsors have been advised specifically of the possibility of such damages, arising from the Index or Product, such as, but not limited to, loss of revenue or anticipated profits or lost business.

UBS assumes sole responsibility for this material, which has not been reviewed by Bloomberg

#### Classification

This product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ss of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus is not subject to the supervision of the Swiss Federal Banking Commission (Eidgenössische Bankenkommission). Therefore, investors in this product are not eligible for the specific investor protection under the CISA.

| UBS Investment Bank is a business group of UBS AG  | Contact:   | UBS AG, P.O. Box, 8098 Zurich   |
|--|--|---|
| This document is for your information only and is not intended to be an offer, or a solicitation<br>of an offer, to buy or sell any financial product. The information and opinions contained in this<br>document have been compiled from or arrived at in good faith from sources believed to be<br>reliable. No representation or warranty, express or implied as to the accuracy or completeness<br>or the information contained herein is made by UBS AG. All opinions expressed herein are<br>subject to change without notice. Futures and Options trading is considered risky, and past<br>performance is not necessarily indicative for future results. Additional note to persons receiving<br>this document in Italy: Any Italian persons receiving this document and requiring further<br>information should contact Giubergia UBS SIM SpA, an affiliate of UBS SA, in Milan. | Institutional Investors:<br>Private Investors:<br>E-Mail:<br>Internet: | Zurich: +41-44-239 68 00*<br>Geneva: +41-22-389 50 05*<br>0848-911-011*<br>derivatives@ubs.com<br>www.ubs.com/keyinvest |
| This document is not intended for distribution into the USA, to U.S. Persons.  |  | he numbers marked with an asterisk (*) may be<br>f these numbers, we shall assume that you consent to                   |



#### **Selling Restrictions**

Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further prospectus or corresponding document relating to this Product in such jurisdiction.

Investors are advised to read the selling restrictions described more fully in the relevant Terms and Conditions of this Product. The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Holders of this Product should seek specific advice before on-selling this Product.

Europe - For EEA jurisdictions (EU member states plus Norway, Iceland and Liechtenstein) that have implemented the EU Prospectus Directive, the Final Terms and Conditions for this Product DO NOT QUALIFY as a prospectus published in accordance with the requirements of the EU Prospectus Directive. Unless and until a prospectus has been published in accordance with the requirements of the EU Directive, this Product may not be offered or sold in EEA jurisdictions that have implemented the EU prospectus Directive other than 1) in minimum denominations of, or total consideration per investor of at least, EUR 50,000 (or equivalent in other currencies) or 2) only to Qualified Investors; and/or (aggregated for all distributors) to less than 100 offerees that are not Qualified Investors per EEA jurisdiction. A "Qualified Investor" is a legal entity that (i) is authorised or regulated to operate in the financial markets or has the sole purpose to invest in securities; or (ii) meets two of the following three criteria (as shown in its last annual or consolidated accounts): (a) an average number of at least 250 employees during the last financial year; (b) a total balance sheet of more than EUR 43,000,000; and (c) an annual net turnover of more than EUR 50,000,000.

For EEA jurisdictions that have not implemented the EU Prospectus Directive, sales must be in compliance with the law of that jurisdiction.

Hong Kong - This Product has not been offered and sold, and each purchaser represents and agrees that it will not offer and sell the Product in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy and sell shares or debentures, whether as principal or agent, or in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32) of Hong Kong or to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance, or in other circumstances which do not result in the document being a "prospectus" within the meaning of the Companies Ordinance. In relation to the issue of this Product, each purchaser represents and agrees that it has not issued and will not issue any advertisement, invitation or document relating to the Product, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the Product which is or is intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the Securities and Futures Ordinance and any rules made thereunder.

Singapore - The following applies subsequent to the coming into force of the amendments to Part XIII of the SFA (as amended by the Securities and Futures (Amendment) Act 2005).

This Document has not been registered as a prospectus with the Monetary Authority of Singapore under the Securities and Futures Act (Cap. 289) of Singapore ("SFA"). Accordingly, this Document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this Product may not be circulated or distributed, nor may this Product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than (i) to an institutional investor specified in Section 274 of the SFA, (ii) to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

In the event where this Product is subscribed or purchased under Section 275 by a relevant person which is:

- a corporation (which is not an accredited investor) the sole business of which is to hold investment and the entire share (a) capital of which is owned by one or more individuals, each of whom is an accredited investor; or
- (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor;

then the shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest in that trust shall not be transferable for six months after that corporation or that trust has acquired this Product under Section 275 except:

- (1) to an institutional investor under Section 274 of the SFA or to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA;
- (2) where no consideration is given for the transfer; or
- by operation of law. (3)

UK - For the purposes of non-discretionary accounts, this Product should not be sold with a consideration of less than 50,000 EUR or equivalent.

USA - This Product may not be sold or offered within the United States or to U.S. persons, the foregoing shall not, however, prohibit sales to U.S. offices of UBS AG.

#### Important Information

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent,

| UBS Investment Bank is a business group of UBS AG  | Contact:   | UBS AG, P.O. Box, 8098 Zurich   |
|--|--|---|
| This document is for your information only and is not intended to be an offer, or a solicitation<br>of an offer, to buy or sell any financial product. The information and opinions contained in this<br>document have been compiled from or arrived at in good faith from sources believed to be<br>reliable. No representation or warranty, express or implied as to the accuracy or completeness<br>or the information contained herein is made by UBS AG. All opinions expressed herein are<br>subject to change without notice. Futures and Options trading is considered risky, and past<br>performance is not necessarily indicative for future results. Additional note to persons receiving<br>this document in Italy: Any Italian persons receiving this document and requiring further<br>information should contact Giubergia UBS SIM SpA, an affiliate of UBS SA, in Milan. | Institutional Investors:<br>Private Investors:<br>E-Mail:<br>Internet: | Zurich: +41-44-239 68 00*<br>Geneva: +41-22-389 50 05*<br>0848-911-011*<br>derivatives@ubs.com<br>www.ubs.com/keyinvest |
| This document is not intended for distribution into the USA, to U.S. Persons.  |  | the numbers marked with an asterisk (*) may be  |

recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.



have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which the termsheet relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this term sheet. UBS's trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells this product to dealers and other financial institutions at a discount to the issue price or rebates to them for their own account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document is for information purposes only and should not be construed as an offer, recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of this product (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This term sheet shall not be copied or reproduced without UBS's prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the securities described herein, save where explicitly stated in the Prospectus. The securities must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

## Final Terms and Conditions / Prospectus:

The prospectus of the security described in this termsheet can be ordered under Tel. 044 / 239 47 03, Fax 044 / 239 21 11 or via E-Mail: <a href="mailto:swiss-prospectus@ubs.com">swiss-prospectus@ubs.com</a> or from your client advisor.

| UBS Investment Bank is a business group of UBS AG  | Contact:   | UBS AG, P.O. Box, 8098 Zurich   |
|--|--|---|
| This document is for your information only and is not intended to be an offer, or a solicitation<br>of an offer, to buy or sell any financial product. The information and opinions contained in this<br>document have been compiled from or arrived at in good faith from sources believed to be<br>reliable. No representation or warranty, express or implied as to the accuracy or completeness<br>or the information contained herein is made by UBS AG. All opinions expressed herein are<br>subject to change without notice. Futures and Options trading is considered risky, and past<br>performance is not necessarily indicative for future results. Additional note to persons receiving<br>this document in Italy: Any Italian persons receiving this document and requiring further<br>information should contact Giubergia UBS SIM SpA, an affiliate of UBS SA, in Milan. | Institutional Investors:<br>Private Investors:<br>E-Mail:<br>Internet: | Zurich: +41-44-239 68 00*<br>Geneva: +41-22-389 50 05*<br>0848-911-011*<br>derivatives@ubs.com<br>www.ubs.com/keyinvest |
| This document is not intended for distribution into the USA, to U.S. Persons.  |  | he numbers marked with an asterisk (*) may be<br>f these numbers, we shall assume that you consent to                   |

this business practice